March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Incidence of Steroid Induced Ocular Hypertension Following Vitreoretinal Surgery With Difluprednate Versus Prednisolone Acetate
Author Affiliations & Notes
  • Jonathan L. Prenner
    Retina Vitreous Center,
    Robert Wood Johnson Med Sch, New Brunswick, New Jersey
  • Daniel B. Roth
    Ophthalmology, Robert Wood Johnson Med School, New Brunswick, New Jersey
  • Howard F. Fine
    Ophthalmology, Robert Wood Johnson Univ Hosp, Eatontown, New Jersey
  • Harold M. Wheatley
    Ophthalmology-UMDNJ,
    Robert Wood Johnson Med Sch, New Brunswick, New Jersey
  • Daniel Connors
    Retina Vitreous Center,
    Robert Wood Johnson Med Sch, New Brunswick, New Jersey
  • Footnotes
    Commercial Relationships  Jonathan L. Prenner, None; Daniel B. Roth, None; Howard F. Fine, None; Harold M. Wheatley, None; Daniel Connors, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 5383. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jonathan L. Prenner, Daniel B. Roth, Howard F. Fine, Harold M. Wheatley, Daniel Connors; Incidence of Steroid Induced Ocular Hypertension Following Vitreoretinal Surgery With Difluprednate Versus Prednisolone Acetate. Invest. Ophthalmol. Vis. Sci. 2012;53(14):5383.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To identify changes in intraocular pressure (IOP) after vitreoretinal surgical procedures in eyes that received either difluprednate ophthalmic emulsion 0.05% (DP) or prednisolone acetate ophthalmic suspension 1% (PA).

Methods: : A retrospective chart review compared a consecutive series of 100 patients who received DP with 100 patients who received PA after vitreoretinal surgery. Data were collected for a three-month period from the time of surgery.

Results: : A significantly higher number of patients treated with DP (34%, n=34) developed increased IOP (>10mm Hg change from baseline and greater than 21) compared with those receiving PA (21%, n=21), (p=0.04). The mean maximum IOP in the DP cohort (28.0 mm Hg) was significantly higher than in the PA cohort (24.3 mm Hg), (p=0.01). Additionally, the rise in IOP from baseline was significantly higher in the DP treated cohort (9.6 mm Hg) than in the PA treated cohort (6.7 mm Hg), (p=0.02).

Conclusions: : Eyes treated with DP after vitreoretinal surgery were at increased risk for developing clinically significant increases in IOP compared with those receiving PA.

Keywords: intraocular pressure • drug toxicity/drug effects • clinical (human) or epidemiologic studies: outcomes/complications 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×